The top 13: What family physicians should know about prostate cancer

Canadian Family Physician

Volumn 54, Issue 2, 2008, Pages 198-203

  Katz, Anne ^a,b,c   Katz, Alan ^c,d  

^a Manitoba Prostate Centre   (Canada)

^b CANCERCARE MANITOBA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d Department of Population Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PROSTATE SPECIFIC ANTIGEN; SILDENAFIL; TADALAFIL; VARDENAFIL;

BLADDER IRRITATION; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL DECISION MAKING; DIARRHEA; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; GENERAL PRACTITIONER; HUMAN; INCONTINENCE; INTERPERSONAL COMMUNICATION; MARITAL THERAPY; MEDICAL RESEARCH; PATIENT CARE; PELVIS PAIN SYNDROME; PENILE FIBROSIS; PENIS ERECTION; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RECTUM CANCER; RECTUM HEMORRHAGE; REVIEW; SEXUAL DYSFUNCTION;

AGE FACTORS; ATTITUDE TO HEALTH; BRACHYTHERAPY; DECISION MAKING; ERECTILE DYSFUNCTION; HUMANS; INTERPERSONAL RELATIONS; MALE; PATIENT EDUCATION AS TOPIC; PELVIC PAIN; PHOSPHODIESTERASE INHIBITORS; PHYSICIANS, FAMILY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; URINARY INCONTINENCE;

EID: 39649088918     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Canadian Cancer Society, National Cancer Institute of Canada. Canadian cancer statistics 2005. Toronto, ON: Canadian Cancer Society; 2005.
2. Sisler JJ, Brown JB, Stewart M. Family physicians' roles in cancer care. Survey of patients on a provincial cancer registry. Can Fam Physician 2004;50:889-96.
3. Cooperberg MR, Moul JW, Carroll P. The changing face of prostate cancer. J Clin Oncol 2005;23:8146-51.
4. Boorjian S, Bianco F, Scardino PT, Eastham JA. Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy? BJU Int 2005;96:773-6.
5. Vickers AJ, Bianco FJ Jr, Boorjian S, Scardino PT, Eastham JA. Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence? Cancer 2005;106:576-80.
6. Lee D, Allareddy V, O'Donnell M, Williams R, Konety B. Does the interval between prostate biopsy and radical prostatectomy affect the immediate postoperative outcome? BJU Int 2006;97:48-50.
7. Graefen M, Walz J, Chun K, Schlomm T, Haese A, Huland H. Reasonable delay of surgical treatment in men with localized prostate cancer - impact on diagnosis? Eur Urol 2005;47:756-60.
8. Harden J, Schafenacker A, Northouse L, Mood D, Smith D, Pienta K, et al. Couples' experiences with prostate cancer: focus group research. Oncol Nurs Forum 2002;29(4):701-9.
9. Crowe H, Costello AJ. Prostate cancer: perspectives on quality of life and impact of treatment on patients and their partners. Urol Nurs 2003;23(4):279-85.
10. Boehmer U, Clark JA. Communication about prostate cancer between men and their wives. J Fam Pract 2001;50(3):226-31.
11. Davison BJ, Gleave ME, Goldenberg SL, Degner LF, Hoffart D, Berkowitz J. Assessing information and decision preferences of men with prostate cancer and their partners. Cancer Nurs 2002;25(1):42-9.
12. Hawes S, Malcarne VL, Ko C, Sadler GR, Banthia R, Sherman S, et al. Identifying problems faced by spouses and partners of patients with prostate cancer. Oncol Nurs Forum 2006;33:807-14.
13. McGregor S. What information patients with localised prostate cancer hear and understand. Patient Educ Couns 2003;49:273-8.
14. Denberg T, Melhado T, Steiner J. Patient treatment preferences in localized prostate carcinoma: the influence of emotion, misconcpetion, and anecdote. Cancer 2006;107:620-30.
15. Gray R, Fitch M, Phillips C, Labrecque M, Klotz L. Presurgery experiences of prostate cancer patients and their spouses. Cancer Pract 1999;7:130-5.
16. Wilson K, Dowling A, Abdolell M, Tannock I. Perception of quality of life by patients, partners and treating physicians. Qual Life Res 2000;9:1041-52.
17. Jacobs JR, Banthia R, Sadler GR, Varni JW, Malcarne VL, Greenbergs HL, et al. Problems associated with prostate cancer: differences of opinion among health care providers, patients, and spouses. Cancer Educ 2002;17(1):33-6.
18. Boehmer U, Babayan RK. Facing erectile dysfunction due to prostate cancer treatment: perspectives of men and their partners. Cancer Invest 2004;22(6):840-8.
19. Burt J, Caelli K, Moore K, Anderson M. Radical prostatectomy: men's experiences and postoperative needs. J Clin Nurs 2005;14(7):883-90.
20. Lepor H, Kaci L. The impact of open radical retropubic prostatectomy on continence and lower urinary tract symptoms: a prospective assessment using validated self-administered outcome instruments. J Urol 2004;171:1216-9.
21. Carlson K, Nitti V. Prevention and management of incontinence following radical prostatectomy. Urol Clin North Am 2001;28:595-612.
22. Moore KN, Estey A. The early post-operative concerns of men after radical prostatectomy. J Adv Nurs 1999;29(5):1121-9.
23. Fagerlin A, Rovner D, Stableford S, Jentoft C, Wei J, Holmes-Rovner M. Patient education materials about the treatment of early-stage prostate cancer: a critical review. Ann Inter Med 2004;140:721-8.
24. O'Rourke ME. Urinary incontinence as a factor in prostate cancer treatment selection. J Wound Ostomy Continence Nurs 2000;27:146-54.
25. Hollenbeck BK, Dunn RL, Wei JT, Montie JE, Sanda MG. Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrument. J Urol 2003;169(4):1453-7.
26. Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol 2005;173(5):1701-5.
27. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000; 283(3):354-60.
28. Clark JA, Inui TS, Silliman RA, Bokhour BG, Krasnow SH, Robinson RA, et al. Patients' perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol 2003;21(20):3777-84.
29. Bokhour BG, Clark JA, Inui TS, Silliman RA, Talcott JA. Sexuality after treatment for early prostate cancer: exploring the meanings of "erectile dysfunction." J Gen Inter Med 2001;16(10):649-55.
30. Penson DF, Latini DM, Lubeck DP, Wallace K, Henning JM, Lue T. Is quality of life different for men with erectile dysfunction and prostate cancer compared to men with erectile dysfunction due to other causes? Results from the ExCEED data base. J Urol 2003;169(4):1458-61.
31. Shabsigh R. Therapy of ED: PDE5 inhibitors. Endocrine 2004;23:135-41.
32. Padma-Nathan H, McCullough A, Forest C. Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies. Curr Urol Rep 2004;5(6):467-71.
33. Raina R, Lakin M, Agarwal A, Mascha E, Montague D, Klein E, et al. Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology 2004;63:960-6.
34. Zagaja G, Mhoon D, Aikens J, Brendler C. Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. Urology 2000;56:631-4.
35. Munding M, Wessells H, Dalkin B. Pilot study of changes in stretched penile lengths 3 months after radical retropubic prostatectomy. Urology 2001;58:567-9.
36. Savoie M, Kim S, Soloway M. A prospective study measuring penile length in men treated with radical prostatectomy for prostate cancer. J Urol 2003;169:1462-4.
37. Fraimen M, Lepor H, McCullough A. Changes in penile morphometrics in men with erectile dysfunction after nerve-sparing prostatectomy. Mol Urol 1999;3:109-15.
38. Mulhall J. Penile length changes after radical prostatectomy. BJU Int 2005;96:472-4.
39. Perugia G, Liberti M, Vicini P, Colistro F, Gentile V. Use of local hyperthermia as prophylaxis of fibrosis and modification in penile length following radical retropubic prostatectomy. Int J Hyperthermia 2005;21:359-65.
40. Moul JW. Variables in predicting survival based on treating "PSA-only" relapse. Urol Oncol 2003;21:292-304.
41. Lieberman R. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk status for the prevention and progression of prostate cancer. Am J Ther 2004;11:501-6.
42. Carroll P. Rising PSA after a radical treatment. Eur Urol 2001;40:9-16.
43. Patel D, Presti JC Jr, McNeal J, Gill H, Brooks J, King C. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 2005;23:6157-62.
44. Merrick GS, Butler W, Wallner K, Allen ZA, Galbreath RW, Lief JH. Brachytherapy-related dysuria. BJU Int 2005;95:597-602.
45. Tsui G, Gillan C, Pond G, Catton C, Crook J. Posttreatment complications of early-stage prostate cancer patients: brachytherapy versus three-dimensional conformal radiation therapy. Cancer J 2005;11(2):122-32.
46. Monga U, Kerrigan A, Thornby J, Monga T, Zimmerman K. Longitudinal study of quality of life in patients with localized prostate cancer undergoing radiotherapy. J Rehabil Res Dev 2005;42(3):391-9.
47. Giordano S, Lee A, Kuo Y, Freeman J, Goodwin J. Late gastrointestinal toxicity after radiation for prostate cancer. Cancer 2006;107:423-32.
48. Baxter N, Tepper J, Durham S, Rothenberger D, Virnig B. Increased risk of rectal cancer after prostate irradiation: A population based study. Gastroenterology 2005;128:819-24.
49. Moon K, Stukenborg G, Keim J, Theodorescu D. Cancer incidence after localized therapy for prostate cancer. Cancer 2006;107:991-8.
50. Kedia S, Zippe CD, Agarwal A, Nelson DR, Lakin MM. Treatment of erectile dysfunction with sildenafil citrate (Viagra) after radiation therapy for prostate cancer. Urology 1999;54(2):308-12.
51. Mulhall J, Ahmed A, Parker M, Mohideen N. The hemodynamics of erectile dysfunction following external beam radiation for prostate cancer. J Sex Med 2005;2(3):432-7.
52. Stone N, Stock R. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology 2007;69:338-42.
53. Schiff J, Bar-Chama N, Cesaretti J, Stock R. Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function. BJU Int 2006;98:1255-8.
54. Grocela J, Mauceri T, Zietman A. New life after brachytherapy? Considering the fertile female partner of the brachytherapy patient. BJU Int 2005;96:781-2.